How Well Does Supplemental Screening Magnetic Resonance Imaging Work in High-Risk Women?
Menée au Canada auprès de 2 207 femmes présentant un risque élevé de développer un cancer du sein (âge : 30 à 69 ans), cette étude évalue, du point de vue du taux de détection, l'efficacité d'un programme annuel de dépistage de la maladie comportant une IRM et une mammographie numérique
There has been much recent criticism of breast cancer screening. Long-term results of randomized controlled trials of mammography on average show a decrease in breast cancer mortality of 22% in women age 50 to 74 years and 15% in women age 39 to 49 years. This benefit to mammography is offset by high rates of false positives, with 10% of women recalled for additional testing each year to diagnose cancer in 0.2% to 0.7% of women screened.
Further, at least some of the cancers found with screening mammography would never otherwise be diagnosed in the patient’s lifetime. Such overdiagnosis results in potentially harmful treatments. The magnitude of such overdiagnosis is a topic of much debate, but is likely to represent at least 10% of all breast cancers found on screening mammography.
Most such overdiagnosis is likely due to low-grade ductal carcinoma in situ (DCIS), and some subcentimeter low-grade, estrogen receptor–positive invasive cancers...
Journal of Clinical Oncology , éditorial, 2014